DuPont de Nemours, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 6, 2019 and accepted by EDGAR at Aug 6, 2019, 17:32 ET.
Management's discussion and analysis
As filed, 80,006 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Effective August 31, 2017, pursuant to the merger of equals transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Historical Dow was determined to be the accounting acquirer in the Merger.
As discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, DowDuPont previously announced its intent to separate into three, independent, publicly traded companies - one for each of its agriculture, materials science and specialty products businesses. DowDuPont formed two wholly owned subsidiaries: Dow Inc. ("Dow", formerly known as Dow Holdings Inc.), to serve as a holding company for its materials science business, and Corteva, Inc. ("Corteva"), to serve as a holding company for its agriculture business.
Effective as of 5:00 p.m. on April 1, 2019, DowDuPont completed the previously announced separation of its materials science business into a separate and independent public company by way of a distribution of Dow through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock, par value $0.01 per share (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).
Effective as of 12:01 a.m. on June 1, 2019, DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.), completed the previously announced separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock, par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “Distributions”).
Following the Corteva Distribution, the Company holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont" (the "Company"). Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD".
These interim Consolidated Financial Statements present the consolidated financial position of DuPont as of June 30, 2019 and December 31, 2018 and the results of operations of DuPont for the three and six months ended June 30, 2019 and 2018 giving effect to the Distributions, with the historical financial results of Dow and Corteva reflected as discontinued operations. The cash flows related to Dow and Corteva have not been segregated and are included, as applicable, in the interim Consolidated Statements of Cash Flows for all periods presented. Unless otherwise indicated, the information included in Management's Discussion and Analysis refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.
The statements of operations and pro forma statements of operations included in this report and as discussed below include costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with Financial Accounting Standards Codification 205, "Presentation of Financial Statements" ("ASC 205") and thus are reflected in the Company's results of continuing operations. A significant portion of these costs relate to Historical Dow and consist of leveraged services provided through service centers, as well as other corporate overhead costs related to information technology, finance, manufacturing, research & development, sales & marketing, supply chain, human resources, sourcing & logistics, legal and communications, public affairs & government affairs functions. These costs are no longer incurred by the Company following the Distributions.
RECENT DEVELOPMENTS
Business Separations and Separation and Distribution Agreements
DuPont completed the separation of Dow on April 1, 2019 and Corteva on June 1, 2019. In connection with the Dow Distribution and Corteva Distribution, DuPont has entered into certain agreements that provide for the allocation of DuPont’s assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among DuPont, Dow, and Corteva (together, the “Parties” and each a “Party”), and provides a framework for DuPont’s relationship with Dow and Corteva following the Distributions. Effective April 1, 2019, the Parties entered into the following agreements:
- Separation and Distribution Agreement - The Parties entered into an agreement that sets forth, among other things, the agreements among the Parties regarding the principal transactions necessary to effect the Distributions. It also sets forth other agreements that govern certain aspects of the Parties’ ongoing relationships after the completion of the Distributions (the "Separation and Distribution Agreement").
- Tax Matters Agreement - The Parties entered into an agreement that governs their respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes.
- Employee Matters Agreement - The Parties entered into an agreement that identifies employees and employee-related liabilities (and attributable assets) to be allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions and describes when and how the relevant transfers and assignments will occur.
- Intellectual Property Cross-License Agreement - DuPont entered into an Intellectual Property Cross-License Agreement with Dow (the “DowDuPont-Dow IP Cross-License Agreement”). The DowDuPont-Dow IP Cross-License Agreement sets forth the terms and conditions under which the applicable Parties may use in their respective businesses, following each of the Distributions, certain know-how (including trade secrets), copyrights, software, and certain patents and standards, allocated to another Party pursuant to the Separation and Distribution Agreement.
In addition to the agreements above, DuPont has entered into certain various supply agreements with Dow. These agreements provide for different pricing than the historical intercompany and intracompany practices prior to the Distributions.
Effective June 1, 2019, in connection with the Corteva Distribution, DuPont and Corteva entered into the following agreements:
- Intellectual Property Cross-License Agreement - DuPont and Corteva entered into an Intellectual Property Cross-License Agreement (the “DuPont-Corteva IP Cross-License Agreement”). The DuPont-Corteva IP Cross-License Agreement sets forth the terms and conditions under which the applicable parties may use in their respective businesses, following the Corteva Distribution, certain know-how (including trade secrets), copyrights, software, and certain patents and standards, allocated to another Party pursuant to the Separation and Distribution Agreement.
- Letter Agreement - The Company entered into a letter agreement (the "Letter Agreement") with Corteva that sets forth certain additional terms and conditions related to the Corteva Distribution, including certain limitations on DuPont’s and Corteva's ability to transfer certain businesses and assets to third parties without assigning certain of such Party’s indemnification obligations under the Separation and Distribution Agreement to the other Party to the transferee of such businesses and assets or meeting certain other alternative conditions. The Letter Agreement further outlines the allocation between DuPont and Corteva of liabilities associated with certain legal and environmental matters, including liabilities associated with discontinued and/or divested operations and businesses of Historical EID. See Note 15 to the interim Consolidated Financial Statements for more information regarding the allocation.
- Amended and Restated Tax Matters Agreement - The Parties entered into an amendment and restatement of the Tax Matters Agreement, between DuPont, Corteva and Dow, effective as of April 1, 2019 (as so amended and restated, the “Amended and Restated Tax Matters Agreement”). The Amended and Restated Tax Matters Agreement governs the Parties’ rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. The Parties amended and restated the Tax Matters Agreement in connection with the Corteva Distribution in order to allocate between the DuPont and Corteva certain rights and obligations of the Company provided in the original form of the Tax Matters Agreement.
Segment Realignment
Effective June 1, 2019, DuPont changed its management and reporting structure resulting in the creation of a new Non-Core segment ("Second Quarter Segment Realignment").
These changes result in the following being realigned to Non-Core:
- Photovoltaic and Advanced Materials business unit (including the HSC Group joint ventures: DC HSC Holdings LLC and Hemlock Semiconductor L.L.C) from the Electronics & Imaging segment;
- Biomaterials and Clean Technologies business units from the Nutrition & Biosciences segment;
- DuPont Teijin Films joint venture from the Transportation & Industrial (formerly Transportation & Advanced Polymers) segment; and
- Sustainable Solutions business unit from the Safety & Construction segment.
In addition, the following changes have occurred:
- Consolidation of the Nutrition & Health business with the Industrial Biosciences business within the Nutrition & Biosciences reportable segment. Previously, Nutrition & Health and Industrial Biosciences were separate operating segments which did not meet the quantitative thresholds.
- Pre-commercial activities related to the Biomaterials business unit was realigned from Corporate to Non-Core, with the remaining pre-commercial activities realigned to the Nutrition & Biosciences segment.
Refer to Notes 4 and 23 to the interim Consolidated Financial Statements for additional information.
Nutrition & Biosciences and Non-Core Goodwill Impairments
During the three months ended June 30, 2019, the Company was required to perform interim impairment tests of its goodwill due to the internal distribution of the specialty products legal entities from Historical EID to DowDuPont (the "Internal SP Distribution") and the Second Quarter Segment Realignment. As a result of the analyses performed, the Company recorded pre-tax, non-cash impairment charges during the three and six months ended June 30, 2019 totaling $1,175 million, of which $933 million related to the Nutrition & Biosciences segment and $242 million related to the Non-Core segment. The charges were recognized in "Goodwill impairment charge" in the interim Consolidated Statements of Operations. Refer to Note 13 of the interim Consolidated Financial Statements.
Equity Method Investment Impairment
During the second quarter of 2019, in connection with the Internal SP Distribution and the impairment of the Industrial Biosciences reporting unit, the Company performed an impairment analysis on the reporting unit's equity method investments. As a result of the analysis performed, the Company recorded pre-tax, non-cash impairment charges of $63 million to write-down the value of an equity method investment. The charge was recognized in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. Refer to Note 5 of the interim Consolidated Financial Statements.
Reverse Stock Split
On May 23, 2019, stockholders of DowDuPont approved a 1-for-3 reverse stock split of DowDuPont shares of common stock with par value of $0.01 per share, which became effective immediately following the Corteva Distribution on June 1, 2019. All comparable periods presented have been retrospectively revised to reflect this change.
Share Buyback Program
On June 1, 2019, the Company's Board of Directors approved a new $2 billion share buyback program, which expires on June 1, 2021. At June 30, 2019, the Company had repurchased 1.4 million shares under this program at a total cost of $102 million.
Dividends
On February 14, 2019, the Company announced that its Board declared a pro rata dividend of $851 million, paid on March 15, 2019, to shareholders of record on February 28, 2019. On March 8, 2019, the Company announced that its Board declared a pro rata dividend of $325 million, paid on May 28, 2019, to shareholders of record on April 26, 2019.
On June 27, 2019, the Company announced that its Board declared a third quarter dividend of $0.30 per share payable on September 13, 2019, to shareholders of record on July 31, 2019.
2019 Restructuring Program
During the second quarter of 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the Distributions. As a result of these actions, the Company expects to record total pre-tax restructuring charges of $85 million to $130 million, comprised of approximately $55 million to $80 million of severance and related benefits costs; $30 million to $45 million of asset related charges; and up to $5 million of costs related to contract terminations. For the three and six months ended June 30, 2019, DuPont recorded a pre-tax charge of $53 million, recognized in "Restructuring and asset related charges - net" in the Company's interim Consolidated Statements of Operations. At June 30, 2019, total liabilities related to the program were $50 million. Future cash payments related to this program are anticipated to be approximately $55 million to $85 million, primarily related to the payment of severance and related benefits and contract termination costs.
DowDuPont Cost Synergy Program
In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program (the “Synergy Program”), adopted by the DowDuPont Board of Directors. The Synergy Program was designed to integrate and optimize the organization following the Merger and in preparation for the Distributions. The Company has recorded pre-tax restructuring charges of $466 million inception-to-date, consisting of severance and related benefit costs of $222 million, asset related charges of $184 million and contract termination charges of $60 million. The Company does not expect to incur further significant charges related to the DowDuPont Cost Synergy program and at June 30, 2019 the program is considered substantially complete.
In connection with these actions, the Company recorded pre-tax charges of $22 million and $94 million for the three and six months ended June 30, 2019, respectively. Future cash payments related to this program are anticipated to be approximately $124 million, primarily related to the payment of severance and related benefits.
SELECTED FINANCIAL DATA
In millions, except per share amounts
| Three Months Ended June 30, 2019 | June 30, 2018 | Six Months Ended June 30, 2019 | June 30, 2018 | |
|---|---|---|---|---|
| Net sales | $5,468 | $5,857 | $10,882 | $11,454 |
| Gross Margin | $1,972 | $1,772 | $3,765 | $3,564 |
| Gross Margin Percentage | 36.1% | 30.3% | 34.6% | 31.1% |
| Research and development expenses | $232 | $270 | $499 | $544 |
| Percent of net sales | 4.2% | 4.6% | 4.6% | 4.7% |
| Selling, general and administrative expenses | $642 | $768 | $1,368 | $1,570 |
| Percent of net sales | 11.7% | 13.1% | 12.6% | 13.7% |
| Effective tax rate - continuing operations | (16.4)% | 76.2% | (5.8)% | 134.4% |
| Net (loss) income available for DuPont common stockholders | $(571) | $1,769 | $(50) | $2,862 |
| (Loss) earnings per common share – basic | $(0.76) | $2.29 | $(0.07) | $3.69 |
| (Loss) earnings per common share – diluted | $(0.76) | $2.27 | $(0.07) | $3.69 |
56
RESULTS OF OPERATIONS
In millions
| Summary of Sales Results | Three Months Ended June 30, 2019 | June 30, 2018 | Six Months Ended June 30, 2019 | June 30, 2018 |
|---|---|---|---|---|
| Net sales | $5,468 | $5,857 | $10,882 | $11,454 |
The following table summarizes sales variances by segment and geographic region from the prior year:
Sales Variances by Segment and Geographic Region
| Percentage change from prior year | Three Months Ended June 30, 2019 Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total | Six Months Ended June 30, 2019 Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Electronics & Imaging | —% | (2)% | (5)% | —% | (7)% | —% | (2)% | (4)% | —% | (6)% |
| Nutrition & Biosciences | 1 | (3) | (1) | (1) | (4) | 1 | (3) | (1) | — | (3) |
| Transportation & Industrial | 5 | (3) | (12) | — | (10) | 6 | (3) | (10) | — | (7) |
| Safety & Construction | 4 | (3) | 1 | (4) | (2) | 4 | (2) | 2 | (4) | — |
| Non-Core | — | (2) | (14) | — | (16) | (2) | (2) | (10) | — | (14) |
| Total | 2% | (3)% | (5)% | (1)% | (7)% | 3% | (3)% | (4)% | (1)% | (5)% |
| U.S. & Canada | 1% | —% | (3)% | —% | (2)% | 1% | —% | (2)% | —% | (1)% |
| EMEA 1 | 3 | (6) | (6) | (4) | (13) | 4 | (6) | (4) | (4) | (10) |
| Asia Pacific | 2 | (3) | (6) | — | (7) | 2 | (3) | (5) | — | (6) |
| Latin America | 4 | (4) | (3) | (1) | (4) | 5 | (4) | (2) | (1) | (2) |
| Total | 2% | (3)% | (5)% | (1)% | (7)% | 3% | (3)% | (4)% | (1)% | (5)% |
1. Europe, Middle East and Africa.
The Company reported net sales for the three months ended June 30, 2019 of $5.5 billion, down 7 percent from $5.9 billion for the three months ended June 30, 2018, due to a 5 percent decrease in volume, a 3 percent unfavorable currency impact and a 1 percent decline in portfolio actions slightly offset a by 2 percent increase in local price. Volume declined across all geographic regions and all segments with the exception of Safety & Construction (up 1 percent). The most notable volume decreases were in Non-Core (down 14 percent) and Transportation & Industrial (down 12 percent). Portfolio and other changes contributed 1 percent of the sales decrease which impacted Safety & Construction (down 4 percent; within EMEA) and Nutrition & Biosciences (down 1 percent). Local price was up 2 percent compared with the same period last year. Local price increased in all geographic regions and in all segments except Electronics & Imaging and Non-core (flat in both). Currency was down 3 percent compared with the same period last year, driven primarily by EMEA currencies (down 6 percent).
Net sales for the six months ended June 30, 2019 were $10.9 billion, down 5 percent from $11.5 billion for the six months ended June 30, 2018, due to a 4 percent decrease in volume, a 3 percent unfavorable currency impact and a 1 percent decline in portfolio actions slightly offset by a 3 percent increase in local price. Volume declined across all geographic regions and in all segments with the exception of Safety & Construction (up 2 percent). The most notable volume decreases were in Transportation & Industrial (down 10 percent) and Non-Core (down 10 percent). Portfolio and other changes decreased 1 percent due to a 4 percent decrease related to Safety & Construction within EMEA. Local price was up 3 percent compared with the same period last year. Local price increased in all geographic regions and in most segments except Electronics & Imaging (flat) and Non-core (down 2 percent). Currency was down 3 percent compared with the same period last year, driven primarily by EMEA currencies (down 6 percent).
Cost of Sales
Cost of sales was $3.5 billion for the three months ended June 30, 2019, down from $4.1 billion for the three months ended June 30, 2018. Cost of sales decreased for the three months ended June 30, 2019 primarily due to lower sales volume, cost synergies, currency impacts, and the absence of costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions.
Cost of Sales as a percentage of net sales for the three months ended June 30, 2019 was 64 percent compared with 70 percent for the three months ended June 30, 2018.
For the six months ended June 30, 2019, cost of sales was $7.1 billion, down from $7.9 billion for the six months ended June 30, 2018. Cost of sales decreased for the six months ended June 30, 2019 primarily due to lower sales volume, cost synergies, currency impacts, and lower costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions. Cost of sales for the six months ended June 30, 2018 was also negatively impacted by a $73 million charge related to amortization of the fair value step-up in Historical EID's inventories as a result of the Merger and the acquisition of FMC Corporation's Health and Nutrition business in November 2017; there were no charges related to this fair value step-up during the first half of 2019.
Cost of sales as a percentage of net sales for the six months ended June 30, 2019 was 65 percent compared with 69 percent for the six months ended June 30, 2018.
Research and Development Expenses ("R&D")
R&D expenses totaled $232 million in the second quarter of 2019, down from $270 million in the second quarter of 2018. R&D as a percentage of net sales was 4 percent and 5 percent for the three months ended June 30, 2019 and 2018, respectively.
For the first six months of 2019, R&D expenses totaled $499 million, down from $544 million in the first six months of 2018. R&D as a percentage of net sales was 5 percent for both the six months ended June 30, 2019 and 2018.
The decrease for the three months ended June 30, 2019 as compared with the same period of the prior year was primarily due to the absence of R&D costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions.
Selling, General and Administrative Expenses ("SG&A")
SG&A expenses were $642 million in the second quarter of 2019, down from $768 million in the second quarter of 2018. SG&A as a percentage of net sales was 12 percent and 13 percent for the three months ended June 30, 2019 and 2018, respectively.
For the first six months of 2019, SG&A expenses totaled $1,368 million, down from $1,570 million in the first six months of 2018. SG&A as a percentage of net sales was 13 percent and 14 percent for the six months ended June 30, 2019 and 2018, respectively.
The decrease for the three months ended June 30, 2019 as compared with the same period of the prior year was primarily due to the absence of SG&A costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions. In addition to the absence of similar SG&A costs related to the discontinued operations for the six months ended June 30, 2019, SG&A decreased due to cost synergies.
Amortization of Intangibles
Amortization of intangibles was $252 million in the second quarter of 2019, down from $266 million in the second quarter of 2018. In the first six months of 2019, amortization of intangibles was $508 million, down from $531 million in the same period last year. See Note 13 to the interim Consolidated Financial Statements for additional information on intangible assets.
Restructuring and Asset Related Charges - Net
Restructuring and asset related charges - net were $137 million and $46 million for the three months ended June 30, 2019 and 2018, respectively. The activity in the second quarter of 2019 was primarily related to a $63 million impairment charge related to an equity method investment, a $53 million charge related to the new 2019 Restructuring Program and a $21 million charge related to the DowDuPont Cost Synergy Program. The charges in the second quarter of 2018 related to the DowDuPont Cost Synergy Program.
Restructuring and asset related charges - net were $208 million and $99 million for the six months ended June 30, 2019 and 2018, respectively. The activity for the six months ended June 30, 2019 was related to the equity method investment impairment charge and 2019 Restructuring Program, both described above, as well as a $92 million charge related to the DowDuPont Cost Synergy Program. The charges in the first half of 2018 related to the DowDuPont Cost Synergy Program.
See Note 5 to the interim Consolidated Financial Statements for additional information.
Goodwill Impairment Charges
Goodwill impairments charges were $1,175 million in the three and six months ended June 30, 2019. The goodwill impairment charges relate to the Nutrition & Biosciences and Non-Core segments. There were no goodwill related impairments in the same periods of 2018. See Note 13 to the interim Consolidated Financial Statements for additional information.
Integration and Separation Costs
Integration and separation costs, primarily reflect costs related to the post-Merger integration and activities related to the Distributions, were $347 million in the second quarter of 2019, down from $428 million in the second quarter of 2018. In the first six months of 2019, integration and separation costs were $958 million, up from $793 million in the same period last year.
Equity in Earnings of Nonconsolidated Affiliates
The Company's share of the earnings of nonconsolidated affiliates was $49 million in the second quarter of 2019, down from $54 million in the second quarter of 2018. In the first six months of 2019, the Company's share of the earnings of nonconsolidated affiliates was $89 million, down from $111 million in the first six months of 2018. The decrease in the 2019 periods is primarily due to lower equity earnings from the HSC Group.
Sundry Income (Expense) - Net
Sundry income (expense) - net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other post employment benefit plan credits or costs, and certain litigation matters. Sundry income (expense) - net in the second quarter of 2019 was a loss of $19 million, compared with income of $82 million in the second quarter of 2018. The second quarter of 2019 included income related to non-operating pension and other post employment benefit credits of $18 million, a gain on sale of assets of $10 million and interest income of $9 million partially offset by foreign currency exchange losses of $17 million and a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement included in miscellaneous income. The second quarter of 2018 included income related to non-operating pension and other post employment benefit credits of $28 million and foreign currency exchange gains of $53 million partially offset by the loss on divestiture and changes in joint venture ownership of $21 million.
In the first six months of 2019, sundry income (expense) - net was income of $65 million compared with a loss of $16 million in the first six months of 2018. In addition to the amounts previously discussed, the first six months of 2019 included income related to non-operating pension and other post employment benefit plans of $39 million, a gain on sale of assets of $63 million and interest income of $49 million partially offset by foreign currency exchange losses of $78 million. The first six months of 2018 included foreign currency exchange losses of $122 million, including a $50 million foreign currency exchange loss related to adjustments to foreign currency exchange contracts as a result of U.S. tax reform. The loss was offset by income related to non-operating pension and other post employment benefit plans of $55 million and miscellaneous income of $45 million. See Notes 6 and 19 to the interim Consolidated Financial Statements for additional information.
Interest Expense
Interest expense was $165 million and $316 million for the three and six months ended June 30, 2019, respectively. There was no interest expense related to continuing operations for the three and six months ended June 30, 2018 as the Company did not have outstanding borrowings until the 2018 Senior Notes issuance in the fourth quarter of 2018.
Provision for Income Taxes on Continuing Operations
The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute. The effective tax rate for the second quarter of 2019 was (16.4) percent, compared with an effective tax rate of 76.2 percent for the second quarter of 2018. For the first six months of 2019, the effective tax rate was (5.8) percent, compared with 134.4 percent for the first six months of 2018.
The negative tax rate in the second quarter of 2019 and for the first six months of 2019, was principally the result of the non-tax-deductible goodwill impairment charges impacting the Nutrition & Biosciences and Non-Core segments. See Note 13 for more information regarding the goodwill impairment charges.
Income from Discontinued Operations, Net of Tax
Income from discontinued operations, net of tax was $566 million and $1,773 million for the three months ended June 30, 2019 and 2018, respectively, and $1,212 million and $2,983 million for the six months ended June 30, 2019 and 2018, respectively. The decreases are attributable to the timing of the Distributions. Refer to Note 3 to the interim Consolidated Financial Statements for additional information.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests, including the portion attributable to discontinued operations, was $34 million in the second quarter of 2019, down from $35 million in the second quarter of 2018. For the first six months of 2019, net income attributable to noncontrolling interests, including the portion attributable to discontinued operations, was $85 million, compared with $79 million for the same period last year.
Net income attributable to noncontrolling interests of continuing operations for the three and six months ended June 30, 2019 was $9 million and $13 million, respectively, as compared to a loss of $2 million and income of $11 million for the same periods in the prior year, respectively.
SUPPLEMENTAL UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
The following supplemental unaudited pro forma financial information (the “unaudited pro forma financial statements”) are derived from DuPont’s Consolidated Financial Statements, adjusted to give effect to certain events directly attributable to the Distributions. In contemplation of the Distributions and to achieve the respective credit profiles of each of the current companies, in the fourth quarter of 2018, DowDuPont borrowed $12.7 billion under the 2018 Senior Notes and entered the Term Loan Facilities with an aggregate principal amount of $3.0 billion. Additionally, DuPont issued approximately $1.4 billion in commercial paper in May 2019 in anticipation of the Corteva Distribution (the “Funding CP Issuance” together with the 2018 Senior Notes and the Term Loan Facilities, the "Financings"). The unaudited pro forma financial statements for the six months ended June 30, 2019 and for three and six months ended June 30, 2018 were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Distributions and the Financings (collectively the "Transactions"), (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. The unaudited pro forma statements of operations for the six months ended June 30, 2019 and for three and six months ended June 30, 2018 give effect to the pro forma events as if they had been consummated on January 1, 2018. There were no pro forma adjustments for the three months ended June 30, 2019.
Restructuring or integration activities or other costs following the Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The unaudited pro forma income statements provides shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information.
The unaudited pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont's results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.
Unaudited Pro Forma Combined Statement of Operations
2018
In millions, except per share amounts
| Three Months Ended June 30, DuPont 1 | Pro Forma Adjustments2 | Pro Forma | |
|---|---|---|---|
| Net sales | $5,857 | $— | $5,857 |
| Cost of sales | 4,085 | 18 | 4,103 |
| Research and development expenses | 270 | — | 270 |
| Selling, general and administrative expenses | 768 | — | 768 |
| Amortization of intangibles | 266 | — | 266 |
| Restructuring and asset related charges - net | 46 | — | 46 |
| Integration and separation costs | 428 | (137) | 291 |
| Equity in earnings of nonconsolidated affiliates | 54 | — | 54 |
| Sundry income (expense) - net | 82 | — | 82 |
| Interest expense | — | 171 | 171 |
| Income (Loss) from continuing operations before income taxes | 130 | (52) | 78 |
| Provision (Credit) for income taxes on continuing operations | 99 | (10) | 89 |
| Income (Loss) from continuing operations, net of tax | 31 | (42) | (11) |
| Net loss attributable to noncontrolling interests of continuing operations | (2) | — | (2) |
| Net income (loss) from continuing operations attributable to DuPont | 33 | (42) | (9) |
| Per common share data: | |||
| Earnings (Loss) per common share from continuing operations - basic | $0.03 | $(0.02) | |
| Earnings (Loss) per common share from continuing operations - diluted | $0.03 | $(0.02) | |
| Weighted-average common shares outstanding - basic | 769.6 | 769.6 | |
| Weighted-average common shares outstanding - diluted | 774.5 | 769.6 |
1. See the historical U.S. GAAP Consolidated Statements of Operations.
2. Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one time transaction costs directly attributable to the Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings.
Unaudited Pro Forma Combined Statement of Operations
In millions, except per share amounts
| 2019 | Six Months Ended June 30, DuPont 1 | Pro Forma Adjustments2 | 2018 Pro Forma | DuPont 1 | Pro Forma Adjustments2 | Pro Forma |
|---|---|---|---|---|---|---|
| Net sales | $10,882 | $— | $10,882 | $11,454 | $— | $11,454 |
| Cost of sales | 7,117 | 22 | 7,139 | 7,890 | 36 | 7,926 |
| Research and development expenses | 499 | — | 499 | 544 | — | 544 |
| Selling, general and administrative expenses | 1,368 | — | 1,368 | 1,570 | — | 1,570 |
| Amortization of intangibles | 508 | — | 508 | 531 | — | 531 |
| Restructuring and asset related charges - net | 208 | — | 208 | 99 | — | 99 |
| Goodwill impairment charge | 1,175 | — | 1,175 | — | — | — |
| Integration and separation costs | 958 | (173) | 785 | 793 | (228) | 565 |
| Equity in earnings of nonconsolidated affiliates | 89 | — | 89 | 111 | — | 111 |
| Sundry income (expense) - net | 65 | — | 65 | (16) | — | (16) |
| Interest expense | 316 | 29 | 345 | — | 342 | 342 |
| (Loss) Income from continuing operations before income taxes | (1,113) | 122 | (991) | 122 | (150) | (28) |
| Provision (Credit) for income taxes on continuing operations | 64 | 30 | 94 | 164 | (31) | 133 |
| (Loss) Income from continuing operations, net of tax | (1,177) | 92 | (1,085) | (42) | (119) | (161) |
| Net income attributable to noncontrolling interests of continuing operations | 13 | — | 13 | 11 | — | 11 |
| Net (loss) income from continuing operations attributable to DuPont | (1,190) | 92 | (1,098) | (53) | (119) | (172) |
| Per common share data: | ||||||
| Loss per common share from continuing operations - basic | $(1.59) | $(1.47) | $(0.09) | $(0.24) | ||
| Loss per common share from continuing operations - diluted | $(1.59) | $(1.47) | $(0.09) | $(0.24) | ||
| Weighted-average common shares outstanding - basic | 749.6 | 749.6 | 771.0 | 771.0 | ||
| Weighted-average common shares outstanding - diluted | 749.6 | 749.6 | 771.0 | 771.0 |
1. See the historical U.S. GAAP Consolidated Statements of Operations.
2. Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one time transaction costs directly attributable to the Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings.
SEGMENT RESULTS
Prior to April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e., pro forma “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post employment benefits (“OPEB”) / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's CODM assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures can be found in Note 23 to the interim Consolidated Financial Statements. Prior year data has been updated to conform with the current year presentation.
Pro forma adjustments used in the calculation of pro forma Operating EBITDA were determined in accordance with Article 11 of Regulation S-X and were derived from DuPont's historical Consolidated Financial Statements and accompanying notes, adjusted to give effect to the Distributions as if they had been consummated on January 1, 2018. The pro forma adjustments impacting pro forma Operating EBITDA reflect the impact of various supply agreements ("supply agreements") entered into in connection with the Dow Distribution and are outlined in the preceding section, Supplemental Unaudited Pro Forma Combined Financial Information, as adjustments to "Cost of sales". The impact of these supply agreements are reflected in pro forma Operating EBITDA for the periods noted above as they are included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three months ended June 30, 2019.
ELECTRONICS & IMAGING
The Electronics & Imaging segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication of semiconductors and integrated circuits, and also provides innovative metallization processes for metal finishing, decorative, and industrial applications. Electronics & Imaging in the advanced printing and packaging graphics industry provides flexographic printing inks, photopolymer plates, and platemaking systems used in digital printing applications for textile, commercial and home-office use. In addition, the segment provides cutting-edge materials for the manufacturing of rigid and flexible displays for advanced-matrix organic light emitting diode ("AMOLED"), and quantum dot applications.
In March 2019, the Company announced plans to invest more than $200 million in its Electronics & Imaging segment to increase capacity for the manufacture of KAPTON® film at its Circleville, Ohio, site due to growing global demand.
In millions
| Electronics & Imaging | Three Months Ended Jun 30, 2019 | Jun 30, 2018 | Six Months Ended Jun 30, 2019 | Jun 30, 2018 |
|---|---|---|---|---|
| Net sales | $858 | $921 | $1,683 | $1,785 |
| Operating EBITDA 1 | $246 | $290 | $534 | $567 |
| Equity earnings | $5 | $6 | $8 | $13 |
1. For the six months ended June 30, 2019 and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
| Electronics & Imaging Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Jun 30, 2019 | Six Months Ended Jun 30, 2019 |
|---|---|---|
| Local price & product mix | —% | —% |
| Currency | (2) | (2) |
| Volume | (5) | (4) |
| Portfolio & other | — | — |
| Total | (7)% | (6)% |
Electronics & Imaging net sales were $858 million for the three months ended June 30, 2019, down from $921 million for the three months ended June 30, 2018. Net sales decreased due to a 5 percent volume decline and a 2 percent unfavorable currency impact, driven primarily by Asia Pacific. Volume gains in Display Technologies were more than offset by softer volumes in Semiconductor Technologies and Interconnect Solutions. Volume growth in Display Technologies reflects increased demand for organic light emitting diode ("OLED") materials. Increased demand for semiconductor packaging materials in Semiconductor Technologies was more than offset by weakened demand in the memory sector. Demand for advanced materials for smartphones remained strong but overall volumes in Interconnect Solutions were down due to soft circuit board demand.
Operating EBITDA was $246 million for the three months ended June 30, 2019, down 15 percent compared with pro forma Operating EBITDA of $290 million for the three months ended June 30, 2018. Cost synergies were more than offset by volume decline and higher raw material costs in the second quarter of 2019 compared with the second quarter of 2018.
Electronics & Imaging net sales were $1,683 million for the six months ended June 30, 2019, down from $1,785 million for the six months ended June 30, 2018. Net sales decreased due to a 4 percent volume decline and a 2 percent unfavorable currency impact, driven primarily by Asia Pacific. Volume growth in Display Technologies driven by increased OLED demand was more than offset by volume declines in Interconnect Solutions and Semiconductor Technologies.
Pro forma Operating EBITDA was $534 million for the six months ended June 30, 2019, down 6 percent compared with $567 million for the six months ended June 30, 2018. Favorable impacts from an asset sale and cost synergies were more than offset by higher raw material costs and volume declines.
NUTRITION & BIOSCIENCES
The Nutrition & Biosciences segment is an innovation-driven and customer-focused segment that provides solutions for the global food and beverage, dietary supplements, home and personal care, energy, animal nutrition and pharma markets. The segment is one of the world's largest producers of specialty ingredients, developing and manufacturing solutions for the global food and beverage, dietary supplements, enzymes and pharmaceutical excipient markets. Additionally, the segment is an industry pioneer and innovator that works with customers to improve the performance, productivity and sustainability of their products and processes, through differentiated technology in ingredients applications, fermentation, biotechnology, chemistry and manufacturing process excellence.
In millions
| Nutrition & Biosciences | Three Months Ended Jun 30, 2019 | Jun 30, 2018 | Six Months Ended Jun 30, 2019 | Jun 30, 2018 |
|---|---|---|---|---|
| Net sales | $1,558 | $1,621 | $3,093 | $3,198 |
| Operating EBITDA 1 | $391 | $383 | $744 | $751 |
| Equity earnings | $— | $— | $— | $1 |
1. For the six months ended June 30, 2019 and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
| Nutrition & Biosciences Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Jun 30, 2019 | Six Months Ended Jun 30, 2019 |
|---|---|---|
| Local price & product mix | 1% | 1% |
| Currency | (3) | (3) |
| Volume | (1) | (1) |
| Portfolio & other | (1) | — |
| Total | (4)% | (3)% |
Nutrition & Biosciences net sales were $1,558 million for the three months ended June 30, 2019, down from $1,621 million for the three months ended June 30, 2018, due to a 1 percent increase in local price, which was more than offset by a 3 percent unfavorable currency impact, a 1 percent decrease in volume and a 1 percent decrease from portfolio actions. Volume gains in Health & Biosciences were more than offset by lower volumes in Food & Beverage and Pharma Solutions. Volume gains in Health & Biosciences were led by increased probiotics and microbial control demand partially offset by volume declines in bioactives resulting from ongoing challenged conditions in U.S. energy markets. Food & Beverage volumes were lower than the same quarter of last year as volume gains in specialty proteins driven by growing demand in the meat-free market were more than offset by declines in functional solutions and emulsifiers & sweeteners. Pharma Solutions volumes declined due to capacity constraints and product mix shift.
Operating EBITDA was $391 million for the three months ended June 30, 2019, up 2 percent compared with pro forma Operating EBITDA of $383 million for the three months ended June 30, 2018 due to cost synergies and pricing gains which were partially offset by unfavorable currency impacts, higher raw material costs and volume declines.
Nutrition & Biosciences net sales were $3,093 million for the six months ended June 30, 2019, down from $3,198 million for the six months ended June 30, 2018. The decrease was due to a 1 percent increase in local price, which was more than offset by a 3 percent unfavorable currency impact and a 1 percent decrease in volume. Volume gains in Food & Beverage as a result of increased demand in cellulosic and proteins were more than offset by volume declines in Health & Biosciences due to decreased biorefinery and microbial control demand.
Pro forma Operating EBITDA was $744 million for the six months ended June 30, 2019, down 1 percent compared with $751 million for the six months ended June 30, 2018. Cost synergies and pricing gains were more than offset by unfavorable currency impacts, higher raw material costs and volume declines.
TRANSPORTATION & INDUSTRIAL
The Transportation & Industrial segment provides high-performance engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The segment delivers a broad range of polymer-based high-performance materials in its product portfolio, including elastomers and thermoplastic and thermoset engineering polymers which are used by customers to fabricate components for mechanical, chemical and electrical systems. In addition, the segment produces innovative engineering polymer solutions, high performance parts, specialty silicones and differentiated adhesive technologies to meet customer specifications in automotive, aerospace, electronics, industrial, healthcare and consumer markets. Transportation & Industrial is a global leader of advanced materials that provides technologies that differentiate customers’ products with improved performance characteristics enabling the transition to hybrid-electric-connected vehicles, High Speed High Frequency connectivity and smart Healthcare.
In millions
| Transportation & Industrial | Three Months Ended Jun 30, 2019 | Jun 30, 2018 | Six Months Ended Jun 30, 2019 | Jun 30, 2018 |
|---|---|---|---|---|
| Net sales | $1,269 | $1,417 | $2,586 | $2,795 |
| Operating EBITDA 1 | $357 | $402 | $730 | $791 |
| Equity earnings | $2 | $1 | $2 | $3 |
1. For the six months ended June 30, 2019 and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
| Transportation & Industrial Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Jun 30, 2019 | Six Months Ended Jun 30, 2019 |
|---|---|---|
| Local price & product mix | 5% | 6% |
| Currency | (3) | (3) |
| Volume | (12) | (10) |
| Portfolio & other | — | — |
| Total | (10)% | (7)% |
Transportation & Industrial net sales were $1,269 million for the three months ended June 30, 2019, down from $1,417 million for the three months ended June 30, 2018. The change in net sales was due to a 5 percent increase in local price which was more than offset by a 12 percent decrease in volume and a 3 percent unfavorable currency impact, primarily in EMEA and Asia Pacific. Volume declines were primarily due to decreased demand in automotive and electronics markets as trade and tariff concerns impact Asia Pacific and EMEA. Local price increased in all regions compared to the same quarter of last year.
Operating EBITDA was $357 million for the three months ended June 30, 2019, down 11 percent compared with pro forma Operating EBITDA of $402 million for the three months ended June 30, 2018 as pricing gains and cost synergies were more than offset by volume declines and unfavorable currency impacts.
Transportation & Industrial net sales were $2,586 million for the six months ended June 30, 2019, down from $2,795 million for the six months ended June 30, 2018 as a 6 percent increase in local price, led by Mobility Solutions, was more than offset by a 10 percent of volume decline and a 3 percent unfavorable currency impact. Volume declines were primarily due to decreased demand in automotive and electronics markets.
Pro forma Operating EBITDA was $730 million for the six months ended June 30, 2019, down 8 percent compared with $791 million for the six months ended June 30, 2018 due to pricing gains and cost synergies, which were more than offset by volume declines, higher raw material costs and unfavorable currency impacts.
SAFETY & CONSTRUCTION
The Safety & Construction segment is a leading provider of engineered products and integrated systems for a number of industries including construction, worker safety, energy, oil and gas, transportation, medical devices and water purification and separation. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier, and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively.
In millions
| Safety & Construction | Three Months Ended Jun 30, 2019 | Jun 30, 2018 | Six Months Ended Jun 30, 2019 | Jun 30, 2018 |
|---|---|---|---|---|
| Net sales | $1,341 | $1,372 | $2,624 | $2,636 |
| Operating EBITDA 1 | $382 | $296 | $756 | $622 |
| Equity earnings | $7 | $8 | $15 | $13 |
1. For the six months ended June 30, 2019 and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
| Safety & Construction Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Jun 30, 2019 | Six Months Ended Jun 30, 2019 |
|---|---|---|
| Local price & product mix | 4% | 4% |
| Currency | (3) | (2) |
| Volume | 1 | 2 |
| Portfolio & other | (4) | (4) |
| Total | (2)% | —% |
Safety & Construction net sales were $1,341 million for the three months ended June 30, 2019, down from $1,372 million for the three months ended June 30, 2018 as a 4 percent increase in local price and 1 percent of volume growth were more than offset by portfolio declines of 4 percent and a 3 percent unfavorable impact from currency. Volume growth in the segment was led by gains in Water Solutions partially offset by declines in Shelter Solutions due to construction slowdown in the U.S. residential market. Safety Solutions volumes were flat compared with the prior year driven by supply constraints.
Operating EBITDA was $382 million for the three months ended June 30, 2019, up 29 percent compared with pro forma Operating EBITDA of $296 million for the three months ended June 30, 2018 due to local price gains, cost synergies, productivity improvements and volume gains partially offset by an unfavorable impact from currency.
Safety & Construction net sales were $2,624 million for the six months ended June 30, 2019, slightly down from $2,636 million for the six months ended June 30, 2018 as a 4 percent increase in local price and 2 percent of volume growth were offset by portfolio declines of 4 percent and a 2 percent unfavorable impact from currency. Volume growth in the segment was led by gains in Water Solutions and Safety Solutions. Safety Solutions growth was driven by strong industrial markets and increased demand in medical packaging and garments. These gains were partially offset by volume declines in Shelter Solutions, primarily due to weakness in the construction global residential market.
Pro forma Operating EBITDA was $756 million for the six months ended June 30, 2019, up 22 percent compared with $622 million for the six months ended June 30, 2018, due to pricing gains, cost synergies and volume growth, partially offset by unfavorable currency impacts.
NON-CORE
The Non-Core segment is a leading global supplier of key materials for the manufacturing of photovoltaics and solar cells, including innovative metallization pastes and backsheet materials for the production of solar cells and solar modules, and components and films for consumer electronics, automotive, and aerospace markets. The segment also includes the Company's share of the results of the HSC Group, a U.S.-based group of companies that manufacture and sell polycrystalline silicon products. In addition, the segment provides sustainable materials and services for sulfuric acid production and regeneration technologies, alkylation technology for production of clean, high-octane gasoline, and a comprehensive suite of aftermarket service and solutions offerings, including safety consulting and services, to improve the safety, productivity, and sustainability of organizations across a range of industries. The Non-Core segment is also a leading producer of specialty biotechnology materials for residential carpet and stretch comfort apparel markets as well as polyester films for the healthcare, photovoltaics, electronics, packaging and labels, and electrical insulation industries.
In millions
| Non-Core | Three Months Ended Jun 30, 2019 | Jun 30, 2018 | Six Months Ended Jun 30, 2019 | Jun 30, 2018 |
|---|---|---|---|---|
| Net sales | $442 | $526 | $896 | $1,040 |
| Operating EBITDA 1 | $99 | $123 | $193 | $233 |
| Equity earnings | $35 | $39 | $64 | $81 |
1. For the six months ended June 30, 2019 and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
| Non-Core Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Jun 30, 2019 | Six Months Ended Jun 30, 2019 |
|---|---|---|
| Local price & product mix | —% | (2)% |
| Currency | (2) | (2) |
| Volume | (14) | (10) |
| Portfolio & other | — | — |
| Total | (16)% | (14)% |
Non-Core net sales were $442 million for the three months ended June 30, 2019, down from $526 million for the three months ended June 30, 2018 due to a 14 percent volume decline and a 2 percent unfavorable impact from currency. Volume declines were driven by weak demand for trichlorosilane due to historically low polysilicon pricing and lower paste sales into electronic component end markets. Biomaterials volume declines were primarily a result of a slow-down in demand in the U.S. residential carpet market.
Operating EBITDA was $99 million for the three months ended June 30, 2019, down 20 percent compared with pro forma Operating EBITDA of $123 million for the three months ended June 30, 2018 mainly due to volume declines and an unfavorable impact from currency.
Non-Core net sales were $896 million for the six months ended June 30, 2019, down from $1,040 million for the six months ended June 30, 2018. Net sales declined due to a 10 percent decline in volume, a 2 percent decline in local price and a 2 percent unfavorable impact from currency. Volume declines were driven by weak demand for trichlorosilane due to historically low polysilicon pricing and lower paste sales into electronic component end markets. Biomaterials volume declines were primarily a result of a slow-down in demand in the U.S. residential carpet market.
Pro forma Operating EBITDA was $193 million for the six months ended June 30, 2019, down 17 percent compared with $233 million for the six months ended June 30, 2018 as cost synergies were more than offset by higher raw material costs, volume declines and an unfavorable impact from currency.
CHANGES IN FINANCIAL CONDITION
Liquidity & Capital Resources
The Company continually reviews its sources of liquidity and debt portfolio and occasionally may make adjustments to one or both to ensure adequate liquidity. The Company’s primary source of incremental liquidity is cash flows from operating activities. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries obligations as they come due.
In millions
| June 30, 2019 | December 31, 2018 | |
|---|---|---|
| Cash, cash equivalents and marketable securities | $1,669 | $8,577 |
| Total debt | $17,229 | $12,639 |
In November 2018, DuPont consummated the offering of the senior unsecured notes (the "2018 Senior Notes") in an aggregate principal amount of $12.7 billion. The offering consisted of $0.5 billion in floating rate notes due November 2020, $0.3 billion in floating rate notes due November 2023, and six tranches of fixed-rate notes: $1.5 billion due November 2020, $2.5 billion due November 2023, $1.85 billion due November 2025, $2.25 billion due November 2028, $1.65 billion due November 2038 and $2.15 billion due November 2048. The net proceeds of the offering after the underwriting discount was $12.6 billion. See Note 14 to the interim Consolidated Financial Statements for additional information on the interest related to the 2018 Senior Notes.
Term Loan and Revolving Credit Facilities
In November 2018, the Company entered into a term loan agreement that establishes two term loan facilities in the aggregate principal amount of $3 billion, (the “Term Loan Facilities”) as well as a five-year $3 billion revolving credit facility (the “Five-Year Revolving Credit Facility”). Effective May 2, 2019, the Company fully drew the two Term Loan Facilities in the aggregate principal amount of $3.0 billion and the Five-Year Revolving Credit Facility became effective and available. In June 2019, the Company entered into a 364-day $750 million revolving credit facility (the “364-Day Revolving Credit Facility”). The Five-Year Revolving Credit Facility is generally expected to remain undrawn, and serve as a backstop to the Company’s commercial paper and letter of credit issuance. The 364-Day Revolving Credit Facility may be drawn against for general corporate purposes, including but not limited to net working capital, costs and expenses.
Commercial Paper
In April 2019, DuPont authorized a $3 billion commercial paper program (the “DuPont Commercial Paper Program”). The Company’s issuance under the Commercial Paper Program included the Funding CP Issuance in May 2019 in anticipation of the Corteva Distribution, as well as borrowings for general corporate purposes.
The net proceeds from the 2018 Senior Notes, Term Loan Facilities, and commercial paper together with cash from operations were used to fund cash contributions to Dow and Corteva, and DowDuPont’s November 2018 $3.0 billion share repurchase program, which was completed in the first quarter of 2019. The remaining proceeds were used to reduce outstanding liabilities of Historical EID that would otherwise be attributed to Corteva; and further pay any related premiums, fees and expenses.
Credit Ratings
The Company's credit ratings impact its access to the debt capital markets and cost of capital. The Company remains committed to a strong financial position and strong investment-grade rating. At July 31, 2019, DuPont's credit ratings were as follows:
| Credit Ratings | Long-Term Rating | Short-Term Rating | Outlook |
| Standard & Poor’s | A- | A-2 | Stable |
| Moody’s Investors Service | Baa1 | P-2 | Stable |
| Fitch Ratings | BBB+ | F-2 | Stable |
The Company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations, subject to certain limitations. The 2018 Senior Notes also contain customary default provisions. The Term Loan Facilities, the Five-Year Revolving Credit Facility and the 364-Day Revolving Credit Facility contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At June 30, 2019, the Company was in compliance with this financial covenant.
The Company's cash, cash equivalents and marketable securities at June 30, 2019 and December 31, 2018 were $1.7 billion and $8.6 billion, respectively, of which $1.6 billion at June 30, 2019 and $2.1 billion at December 31, 2018 were held by subsidiaries in foreign countries, including United States territories. The decrease in cash and cash equivalents held by subsidiaries in foreign countries is due to the repatriation activities discussed below. For each of its foreign subsidiaries, the Company makes an assertion regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States.
The Tax Cuts and Jobs Act (“The Act”) requires companies to pay a one-time transition tax on earnings of foreign subsidiaries, a majority of which were previously considered permanently reinvested by the Company (see Note 7 to the interim Consolidated Financial Statements for further details of The Act). The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' operational activities and future foreign investments. The Company has the ability to repatriate additional funds to the U.S., which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes and the impact of foreign currency movements. It is not practicable to calculate the unrecognized deferred tax liability on undistributed foreign earnings due to the complexity of the hypothetical calculation. During the first and second quarters of 2019, in connection with the Intended Business Separations, the Company repatriated certain funds from its non-U.S. subsidiaries that are not needed to finance local operations or separation activities. For the first quarter of 2019, the Company recorded tax expense of $10 million, associated with these repatriation activities. There were no charges associated with these repatriation activities in the second quarter of 2019.
Summary of Cash Flows
The Company’s cash flows from operating, investing and financing activities, as reflected in the interim Consolidated Statements of Cash Flows, are summarized in the following table. The cash flows related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows for all periods presented, as applicable.
In millions
| Cash Flow Summary Cash provided by (used for): | Six Months Ended June 30, 2019 | June 30, 2018 |
|---|---|---|
| Operating activities | $(51) | $(47) |
| Investing activities | $(1,657) | $(390) |
| Financing activities | $(10,661) | $(3,602) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $48 | $(171) |
| Cash, cash equivalents and restricted cash reclassified as discontinued operations | $— | $7,961 |
Cash Flows from Operating Activities
In the first six months of 2019, cash used for operating activities was $51 million, compared with cash used for operating activities of $47 million in the same period last year. The increase in the use of cash was primarily due to the impact of the Dow and Corteva Distributions to period earnings, largely counter-balanced by lesser use of cash for net working capital versus the prior period.
| Net Working Capital 1 In millions (except ratio) | June 30, 2019 | Dec 31, 2018 |
|---|---|---|
| Current assets | $10,623 | $16,380 |
| Current liabilities | 6,457 | 3,878 |
| Net working capital | $4,166 | $12,502 |
| Current ratio | 1.65:1 | 4.22:1 |
1. Net working capital has been restated to exclude the assets and liabilities related to the Distributions. The assets and liabilities related to the Distributions are presented as assets of discontinued operations and liabilities of discontinued operations, respectively, in the Condensed Consolidated Balance Sheets for all periods presented.
Cash Flows from Investing Activities
In the first six months of 2019, cash used for investing activities was $1,657 million, compared to cash used for investing of $390 million in the first six months of 2018. The increase in cash used was primarily attributable to increased capital expenditures, a decrease in sales and maturities of investments, as well as a decline in trade accounts receivable conduits.
Cash Flows from Financing Activities
In the first six months of 2019, cash used for financing activities was $10,661 million compared with $3,602 million in the same period last year. The primary driver of the increased use of cash is the cash held by Dow and Corteva at the respective Distributions, reflecting cash on the balance sheet of each at the time of their respective spinoff; as well as payments of long-term debt of Historical Dow and Historical EID prior to the Distributions. These uses were partly offset by issuance of long-term debt in the form of the Term Loan Facilities draw in May 2019.
Free Cash Flow
The Company defines free cash flow as cash from operating activities less capital expenditures. Under this definition, free cash flow represents the cash generated by the Company from operations after investing in its asset base. Free cash flow, combined with cash balances and other sources of liquidity, represent the cash available to fund obligations and provide returns to shareholders. Free cash flow is an integral financial measure used in the Company's financial planning process. This financial measure is not recognized in accordance with U.S. GAAP and should not be viewed as an alternative to U.S. GAAP financial measures of performance. All companies do not calculate non-GAAP financial measures in the same manner and, accordingly, the Company's free cash flow definition may not be consistent with the methodologies used by other companies.
For additional information relating to the change in cash used for operating activities, see the discussion in the previous section entitled "Cash Flows from Operating Activities."
In millions
| Reconciliation of "Cash From Operating Activities" to Free Cash Flow (non-GAAP) | Six Months Ended June 30, 2019 | June 30, 2018 |
|---|---|---|
| Cash from operating activities (GAAP) | $(51) | $(47) |
| Capital expenditures | (1,800) | (1,586) |
| Free cash flow (non-GAAP) | $(1,851) | $(1,633) |
Dividends
On February 14, 2019, the Company announced that its Board declared a dividend of $851 million in aggregate on a pro rata basis, paid on March 15, 2019, to shareholders of record on February 28, 2019. On March 8, 2019, the Company announced that its Board declared a dividend of $325 million in the aggregate on a pro rata basis, which was paid on May 28, 2019, to shareholders of record on April 26, 2019.
On June 27, 2019, the Company announced that its Board declared a third quarter dividend of $0.30 per share payable on September 13, 2019, to shareholders of record on July 31, 2019.
Share Buyback Programs
On June 1, 2019, the Company's Board of Directors authorized a new $2 billion share buyback program, which expires on June 1, 2021. At June 30, 2019, the Company had repurchased 1.4 million shares under this program at a total cost of $102 million.
See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.
Pension and Other Post Employment Plans
DuPont expects to make additional contributions in the aggregate of approximately $240 million by year-end 2019 to certain non-US pension and other post employment benefit plans. Any such contribution could be funded by existing cash balances and/or cash from other available sources of liquidity.
Restructuring
Future cash payments related to the 2019 Restructuring Program are anticipated to be approximately $55 million to $85 million, primarily related to the payment of severance and related benefits, lease termination costs, and contract termination costs. The activities related to the DowDuPont Cost Synergy Program are expected to result in additional cash expenditures of approximately $124 million consisting of severance and related benefit costs and contract terminations. Actions associated with the DowDuPont Cost Synergy Program, including employee separations, are considered substantially complete (see Note 5 to the interim Consolidated Financial Statements). It is possible that additional charges and future cash payments could occur in relation to the Company's restructuring actions. The Company expects to incur additional employee-related costs, including involuntary termination benefits, related to its other optimization activities. These costs cannot be reasonably estimated at this time.
Off-balance Sheet Arrangements
Guarantees arise in the ordinary course of business from relationships with customers and nonconsolidated affiliates when the Company undertakes an obligation to guarantee the performance of others if specific triggering events occur. At June 30, 2019 and December 31, 2018, the Company had directly guaranteed $185 million and $199 million, respectively, of such obligations. Additional information related to the guarantees of the Subsidiaries can be found in the “Guarantees” section of Note 15 to the interim Consolidated Financial Statements.
Contractual Obligations
Information related to the Company's contractual obligations at December 31, 2018 can be found in the Company's 2018 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Contractual Obligations. There have been material changes in the Company's contractual obligations since December 31, 2018 as a result of the distributions of Dow and Corteva. Information related to DuPont's significant contractual obligations is summarized in the following table:
In millions
| Total at June 30, 2019 | Payments Due In Remainder of 2019 | 2020-2021 | 2022-2023 | 2024 and beyond | |
|---|---|---|---|---|---|
| Long-term debt obligations 1,2 | $15,713 | $3 | $2,009 | $5,801 | $7,900 |
| Expected cash requirements for interest 3 | 7,640 | 345 | 1,306 | 1,062 | 4,927 |
| Finance lease obligations | 4 | 1 | 2 | — | 1 |
| Operating leases | 612 | 92 | 221 | 120 | 179 |
| Pension and other post employment benefits | 1,184 | 237 | 138 | 123 | 686 |
| Purchase obligations 4 | 647 | 108 | 312 | 179 | 48 |
| Other liabilities 5 | 178 | 27 | 73 | 24 | 54 |
| Total contractual obligations | $25,978 | $813 | $4,061 | $7,309 | $13,795 |
1. Included in the interim Consolidated Financial Statements.
2. Excludes unamortized debt fees of $103 million.
3. Cash requirement for interest on long-term debt was calculated using current interest rates at June 30, 2019 and includes $383 million of various floating rate notes and debt instruments.
4. Represents enforceable and legally binding agreements in excess of $1 million to purchase goods or services that specify fixed or minimum quantities; fixed, minimum or variable price provisions; and the approximate timing of the agreement.
5. Includes liabilities related to environmental remediation, legal settlements, and other noncurrent liabilities. The table excludes uncertain tax positions due to uncertainties in the timing of the effective settlement of tax positions with the respective taxing authorities and deferred tax liabilities as it is impractical to determine whether there will be a cash impact related to these liabilities. The table also excludes deferred revenue as it does not represent future cash requirements arising from contractual payment obligations.
The Company expects to meet its contractual obligations through its normal sources of liquidity and believes it has the financial resources to satisfy the contractual obligations that arise in the ordinary course of business.
OTHER MATTERS
Recent Accounting Guidance
See Note 2 to the interim Consolidated Financial Statements for a description of recent accounting guidance.
Critical Accounting Estimates
The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported in the interim Consolidated Financial Statements and accompanying notes. Note 1 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (“2018 Annual Report”) describes the significant accounting policies and methods used in the preparation of the Consolidated Financial Statements. DuPont’s accounting policies that are impacted by judgments, assumptions and estimates are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s 2018 Annual Report. Since December 31, 2018, there have been no material changes in the Company’s accounting policies that are impacted by judgments, assumptions and estimates. See the discussion in this section for information regarding the valuation of assets and impairment considerations.
Valuation of Assets and Impairment Considerations
The Company tests goodwill for impairment annually during the fourth quarter, or more frequently when events or changes in circumstances indicate that the fair value is below its carrying value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The Company performs goodwill impairment testing at the reporting unit level which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The Company aggregates certain components into reporting units based on economic similarities. The Company assessed and re-defined certain reporting units effective June 1, 2019 in connection with the Second Quarter Segment Realignment. At June 30, 2019, the Company had identified 11 reporting units, eight of which carried goodwill.
During the second quarter 2019, the Company recorded goodwill impairment charges of $1,175 million. Refer to Note 13 to the interim Consolidated Financial Statements for further information.
As a result of the related acquisition method of accounting in connection with the Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that any declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment. There were no other indicators for the Company’s other reporting units that would suggest that it is more likely than not that the fair value is less than its carrying value at June 30, 2019. The Company will perform its annual goodwill and intangible asset impairment test in the fourth quarter.
Market risk
As filed, 4,046 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s global operations are exposed to financial market risks relating to fluctuations in foreign currency exchange rates, commodity prices, and interest rates. The Company has established a variety of programs including the use of derivative instruments and other financial instruments to manage the exposure to financial market risks as to minimize volatility of financial results. In the ordinary course of business, the Company enters into derivative instruments to hedge its exposure to foreign currency, interest rate and commodity price risks under established procedures and controls. For additional information on these derivatives and related exposures, see Note 21 to the interim Consolidated Financial Statements. Decisions regarding whether or not to hedge a given commitment are made on a case-by-case basis, taking into consideration the amount and duration of the exposure, market volatility and economic trends. Foreign currency exchange contracts are also used, from time to time, to manage near-term foreign currency cash requirements.
Foreign Currency Exchange Rate Risks
The Company has significant international operations resulting in a large number of currency transactions that result from international sales, purchases, investments and borrowings. The primary currencies for which the Company has an exchange rate exposure are the European euro ("EUR"), Chinese renminbi, Swiss franc, and South Korean won. The Company uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. In addition to the contracts disclosed in Note 21 to the interim Consolidated Financial Statements, from time to time, the Company will enter into foreign currency exchange contracts to establish with certainty the U.S. dollar ("USD") amount of future firm commitments denominated in a foreign currency.
The following table illustrates the fair values of outstanding foreign currency contracts at June 30, 2019, and the effect on fair values of a hypothetical adverse change in the foreign exchange rates that existed at June 30, 2019. The sensitivities for foreign currency contracts are based on a 10 percent adverse change in foreign exchange rates.
In millions
| Fair Value Asset/(Liability) June 30, 2019 | Fair Value Sensitivity June 30, 2019 | |
|---|---|---|
| Foreign currency contracts | $7 | $(285) |
Since the Company's risk management programs are highly effective, the potential loss in value for each risk management portfolio described above would be largely offset by changes in the value of the underlying exposure.
Concentration of Credit Risk
The Company maintains cash and cash equivalents, marketable securities, derivatives and certain other financial instruments with various financial institutions. These financial institutions are generally highly rated and geographically dispersed and the Company has a policy to limit the dollar amount of credit exposure with any one institution.
As part of the Company's financial risk management processes, it continuously evaluates the relative credit standing of all of the financial institutions that service DuPont and monitors actual exposures versus established limits. The Company has not sustained credit losses from instruments held at financial institutions.
The Company's sales are not materially dependent on any single customer. As of June 30, 2019, no one individual customer balance represented more than five percent of the Company's total outstanding receivables balance. Credit risk associated with its receivables balance is representative of the geographic, industry and customer diversity associated with the Company's global product lines.
The Company also maintains strong credit controls in evaluating and granting customer credit. As a result, it may require that customers provide some type of financial guarantee in certain circumstances. Length of terms for customer credit varies by industry and region.
Controls and procedures
As filed, 1,543 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company’s Disclosure Committee and the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to paragraph (b) of Exchange Act Rules 13a-15 and 15d-15. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
In connection with the Distributions, there are several processes, policies, operations, technologies and information systems that were integrated following the Merger which have been or will be replicated, transferred or separated. The Company continues to take steps to ensure that adequate controls are designed and maintained throughout this transition period.
DuPont de Nemours Inc. PART II - OTHER INFORMATION
Risk factors
As filed, 51,491 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company's operations could be affected by various risks, many of which are beyond its control. Based on current information, the Company believes that the following identifies the most significant risk factors that could affect its operations. Past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.
Risks Relating to the Separations and Distributions
DuPont is subject to continuing contingent tax-related liabilities of Dow and Corteva following the separations and Distributions.
After the separations and Distributions, there are several significant areas where the liabilities of Dow and Corteva may become the Company’s obligations, either in whole or in part. For example, to the extent that any subsidiary of the Company was included in the consolidated tax reporting group of either Historical Dow or Historical EID for any taxable period or portion of any taxable period ending on or before the effective date of the Merger, such subsidiary is jointly and severally liable for the U.S. federal income tax liability of the entire consolidated tax reporting group of Historical Dow or Historical EID, as applicable, for such taxable period. In connection with the separations and Distributions, DuPont, Dow and Corteva have entered into a Tax Matters Agreement, as amended, that allocates the responsibility for prior period consolidated taxes among Dow, Corteva and DuPont. If Dow or Corteva are unable to pay any prior period taxes for which it is responsible, however, DuPont could be required to pay the entire amount of such taxes, and such amounts could be significant. Other provisions of federal, state, local, or foreign law may establish similar liability for other matters, including laws governing tax-qualified pension plans, as well as other contingent liabilities.
Restrictions under the intellectual property cross-license agreements will limit the Company’s ability to develop and commercialize certain products and services and/or prosecute, maintain and enforce certain intellectual property.
Following the separations and Distributions, DuPont is dependent to a certain extent on Dow and Corteva to prosecute, maintain and enforce certain of the intellectual property licensed under the intellectual property cross-license agreements entered into by DuPont, Dow and Corteva in connection with the separations and Distributions. For example, Dow and Corteva are responsible for filing, prosecuting and maintaining (at their respective discretion) patents that Dow and Corteva, respectively, license to the Company. Dow or Corteva, as applicable, will also have the first right to enforce their respective patents, trade secrets and know-how licensed to the Company. If Dow or Corteva, as applicable, fails to fulfill its obligations or chooses to not enforce the licensed patents, trade secrets or know-how under the intellectual property cross-license agreements, DuPont may not be able to prevent competitors from making, using and selling competitive products and services.
In addition, the Company’s use of the intellectual property licensed to it under the intellectual property cross-license agreements is restricted to certain fields, which could limit the Company’s ability to develop and commercialize certain products and services. For example, the licenses granted to it under the agreements do not extend to all fields of use that DuPont may in the future decide to enter. These restrictions may make it more difficult, time consuming and/or expensive for it to develop and commercialize certain new products and services, or may result in certain of the Company’s products or services being later to market than those of the Company’s competitors.
Certain of the contracts transferred or assigned to it as part of the separations and Distributions contain provisions requiring the consent of a third party in connection with the transactions contemplated by the separations and Distributions. If such consent is not given, DuPont may not be entitled to the benefit of such contracts in the future.
Certain of the contracts transferred or assigned to it in connection with the separations and Distributions contain provisions that require the consent of a third party. Some parties may use consent requirements or other rights to seek to terminate contracts or obtain more favorable contractual terms from it. If DuPont is unable to obtain such consents on commercially reasonable and satisfactory terms, the Company’s ability to obtain the benefit of such contracts in the future may be impaired and DuPont may be required to seek alternative arrangements which may be less advantageous to it.
The Company’s customers, prospective customers, suppliers or other companies with whom DuPont conducts business may need assurances that the Company’s financial stability on a stand-alone basis is sufficient to satisfy their requirements for doing or continuing to do business with them.
Some of the Company’s customers, prospective customers, suppliers or other companies with whom DuPont conducts business may need assurances that the Company’s financial stability on a stand-alone basis is sufficient to satisfy their requirements for doing or continuing to do business with them, and may require it to provide additional credit support, such as letters of credit or other financial guarantees. Obtaining such credit support could increase the Company’s costs. Any failure of parties to be satisfied with the Company’s financial stability could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.
Non-compete restrictions in the Separation and Distribution Agreement limit the Company’s ability to compete with certain businesses of Dow for certain periods of time and may limit strategic transactions or discourage the Company’s potential investors from purchasing the Company’s securities. Moreover, when the non-compete restrictions expire, Dow may re-enter these limited business areas, which could cause DuPont to lose market share.
Pursuant to the Separation and Distribution Agreement, and subject to specified exceptions, DuPont and Dow agree not to compete in limited areas of the other’s businesses for a period 30 months from the date of the Dow Distribution. As a result, even if market conditions or the Company’s strategic direction change, DuPont would not be able to enter the subject materials science businesses during the non-compete period. This non-compete restriction could delay, defer or prevent a change of control, merger, consolidation, takeover or other business combination involving it that the Company’s board of directors or the Company’s shareholders may otherwise support, and could also discourage a potential investor from acquiring the Company’s securities and may harm the market price of the Company’s securities, including the Notes.
Once the non-compete period terminates, Dow could elect to re-enter the Company’s subject business areas, in which case DuPont would face increased competition. This may cause it to lose market share and could have an adverse effect on the Company’s business, financial condition, results of operations and cash flows.
In connection with the separations and Distributions, certain liabilities are allocated to or retained by DuPont through assumption or indemnification of Dow and/or Corteva, as applicable. If DuPont is required to make payments pursuant to these indemnities to Dow and/or Corteva, DuPont may need to divert cash to meet those obligations, and the Company’s financial results could be negatively impacted. In addition, certain liabilities are allocated to or retained by Dow and/or Corteva through assumption or indemnification, or subject to indemnification by other third parties. These indemnities may not be sufficient to insure the Company against the full amount of liabilities allocated to or retained by it, and Dow and/or Corteva may not be able to satisfy its indemnification obligations in the future.
Pursuant to the Separation and Distribution Agreement, the Employee Matters Agreement, and the Tax Matters Agreement, as amended, (collectively, the “Core Agreements”) with Dow and Corteva, as well as the Letter Agreement between DuPont and Corteva, DuPont has agreed to assume, and indemnify Dow and Corteva for, certain liabilities. (See discussion of the Core Agreements in Note 3 to the interim Consolidated Financial Statements and Litigation and Environmental Matters in Note 15 to the interim Consolidated Financial Statements.) Payments pursuant to these indemnities may be significant and could negatively impact the Company’s business, particularly indemnities relating to the Company’s actions that could impact the tax-free nature of the distributions. Third parties could also seek to hold it responsible for any of the liabilities allocated to Dow and Corteva, including those related to Historical EID’s materials science and/or agriculture businesses, or for the conduct of such businesses prior to the distributions, and such third parties could seek damages, other monetary penalties (whether civil or criminal) and/or other remedies. Additionally, DuPont generally assumes and is responsible for the payment of the Company’s share of (i) certain liabilities of DowDuPont relating to, arising out of or resulting from certain general corporate matters of DuPont and (ii) certain separation expenses not otherwise allocated to Corteva or Dow (or allocated specifically to it) pursuant to the Core Agreements, and third parties could seek to hold it responsible for Dow’s or Corteva’s share of any such liabilities. Dow and/or Corteva, as applicable, have agreed to indemnify it for such liabilities; however, such indemnities may not be sufficient to protect it against the full amount of such liabilities or from other remedies, and Dow and/or Corteva, as applicable, may not be able to fully satisfy their indemnification obligations. Even if DuPont ultimately succeeds in recovering from Dow and/or Corteva, as applicable, any amounts for which DuPont are held liable, DuPont may be temporarily required to bear these losses. Each of these risks could negatively affect the Company’s business, financial condition, results of operations and cash flows.
Generally, as described in Litigation and Environmental Matters, losses related from liabilities related to discontinued and/or divested operations and businesses of Historical EID that are not primarily related to its agriculture business or specialty products business, (“Stray Liabilities”), are allocated to or shared by each of Corteva and DuPont. Certain Stray Liabilities are subject to third party indemnities; however, such indemnities may not be sufficient to protect the Company against the full amount of such liabilities or such third parties may refuse or otherwise claim defenses to payment. Although the Company believes it is remote, there can be no assurance that any such third party would have adequate resources to satisfy its indemnification obligation when due, or, would not ultimately be successful in claiming defenses against payment. Even if recovery from the third party is ultimately successful, DuPont may be temporarily required to bear these losses. Each of these risks could negatively affect the Company’s business, financial condition, results of operations and cash flows.
If the completed distribution of Corteva or Dow, in each case, together with certain related transactions, were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax and indemnification liability.
The completed distributions of Corteva and Dow were each conditioned upon the receipt of an opinion from Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s tax counsel, regarding the qualification of the applicable distribution along with certain related transactions as a tax-free transaction under Section 355 and Section 368(a)(1)(D) of the Internal Revenue Code of 1986, as amended (the “Code,” and such opinions, collectively, the “Tax Opinions”). The Tax Opinions relied on certain facts, assumptions, and undertakings, and certain representations from the Company, Dow and Corteva, as applicable, as well as the IRS Ruling (as defined below). Notwithstanding the Tax Opinions and the IRS Ruling, the Internal Revenue Service (the “IRS”) could determine on audit that either, or both, of the distributions and certain related transactions should be treated as taxable transactions if it determines that any of these facts, assumptions, representations or undertakings are not correct or have been violated, or that the distributions should be taxable for other reasons, including if the IRS were to disagree with the conclusions of the Tax Opinions.
Even if a distribution otherwise constituted a tax-free transaction to stockholders under Section 355 of the Code, the Company could be required to recognize corporate level tax on such distribution and certain related transactions under Section 355(e) of the Code if the IRS determines that, as a result of the Merger or other transactions considered part of a plan with such distribution, there was a 50 percent or greater change in ownership in the Company, Dow or Corteva, as relevant. In connection with the Merger, the Company sought and received a private letter ruling from the IRS regarding the proper time, manner and methodology for measuring common ownership in the stock of the Company, Historical EID and Historical Dow for purposes of determining whether there was a 50 percent or greater change of ownership under Section 355(e) of the Code as a result of the Merger (the “IRS Ruling”). The Tax Opinions relied on the continued validity of the IRS Ruling and representations made by the Company as to the common ownership of the stock of Historical Dow and Historical EID immediately prior to the Merger, and concluded that there was not a 50 percent or greater change of ownership for purposes of Section 355(e) as a result of the Merger. Notwithstanding the Tax Opinions and the IRS Ruling, the IRS could determine that a distribution or a related transaction should nevertheless be treated as a taxable transaction to the Company if it determines that any of the Company’s facts, assumptions, representations or undertakings was not correct or that a distribution should be taxable for other reasons, including if the IRS were to disagree with the conclusions in the Tax Opinions that are not covered by the IRS Ruling.
Generally, corporate taxes resulting from the failure of a distribution to qualify for non-recognition treatment for U.S. federal income tax purposes would be imposed on the Company. Under the Tax Matters Agreement, as amended, that the Company entered into with Dow and Corteva, Dow and Corteva are generally obligated to indemnify the Company against any such taxes imposed on it. However, if a distribution fails to qualify for non-recognition treatment for U.S. federal income tax purposes for certain reasons relating to the overall structure of the Merger and the distributions, then under the Tax Matters Agreement, as amended, the Company and Corteva, on the one hand, and Dow, on the other hand, would share the tax liability resulting from such failure in accordance with the relative equity values of the Company and Dow on the first full trading day following the distribution of Dow, and the Company and Corteva would in turn share any such resulting tax liability in accordance with the relative equity values of the Company and Corteva on the first full trading day following the distribution of Corteva. Furthermore, under the terms of the Tax Matters Agreement, as amended, a party also generally will be responsible for any taxes imposed on the other parties that arise from the failure of either distribution to qualify as tax-free for U.S. federal income tax purposes within the meaning of Section 355 of the Code or the failure of certain related transactions to qualify for tax-free treatment, to the extent such failure to qualify is attributable to actions, events or transactions relating to such party, or such party's affiliates’, stock, assets or business, or any breach of such party's representations made in connection with the IRS Ruling or in any representation letter provided to a tax advisor in connection with certain tax opinions, including the Tax Opinions, regarding the tax-free status of the distributions and certain related transactions. To the extent that the Company is responsible for any liability under the Tax Matters Agreement, as amended, there could be a material adverse impact on the Company's business, financial condition, results of operations and cash flows in future reporting periods.
The separations and Distributions may expose the Company to potential liabilities arising out of state and federal fraudulent conveyance laws and legal distribution requirements.
Although DuPont received a solvency opinion from an investment bank confirming that DuPont, Dow and Corteva would each be adequately capitalized following the separations and Distributions, the separations and Distributions could be challenged under various state and federal fraudulent conveyance laws. Fraudulent conveyances or transfers are generally defined to include transfers made or obligations incurred with the actual intent to hinder, delay or defraud current or future creditors or transfers made or obligations incurred for less than reasonably equivalent value when the debtor was insolvent, or that rendered the debtor insolvent, inadequately capitalized or unable to pay its debts as they become due. Any unpaid creditor could claim that DuPont did not receive fair consideration or reasonably equivalent value in the separations and distributions, and that the separations and distributions left DuPont insolvent or with unreasonably small capital or that DuPont intended or believed DuPont would incur debts beyond the Company’s ability to pay such debts as they mature. If a court were to agree with such a plaintiff, then such court could void the separations and distributions as a fraudulent transfer or impose substantial liabilities on it, which could adversely affect the Company’s financial condition and the Company’s results of operations.
The separations and Distributions are also subject to review under state corporate distribution statutes. Under the Delaware General Corporation Law, a corporation may only pay dividends to its stockholders either (i) out of its surplus (net assets minus capital) or (ii) if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Although DuPont’s Board of Directors made the distributions out of DuPont’s surplus and received an opinion that
DuPont had adequate surplus under Delaware law to declare the dividends of Corteva and Dow common stock in connection with the Distributions, there can be no assurance that a court will not later determine that some or all of the distributions were unlawful.
Risks Related to DuPont’s Operations After the Separations and Distributions
Changes in the Company’s credit ratings could increase the Company’s cost of borrowing or restrict the Company’s ability to access debt capital markets. The Company’s credit ratings are important to the Company’s cost of capital.
DuPont relies on access to the debt capital markets and other short-term borrowings to finance the Company’s long-term and day-to-day operations. A decrease in the ratings assigned to it by the ratings agencies may negatively impact the Company’s access to the debt capital markets and increase the Company’s cost of borrowing. The major rating agencies will routinely evaluate the Company’s credit profile and assign debt ratings to it. This evaluation is based on a number of factors, which include weighing the Company’s financial strength versus business, industry and financial risk. The addition of further leverage to the Company’s capital structure could impact the Company’s credit ratings. Failure to maintain an investment grade rating at the Company’s current level would adversely affect the Company’s cost of funding and the Company’s results of operations and could adversely affect the Company’s liquidity and access to the capital markets. Any limitation on the Company’s ability to continue to raise money in the debt capital markets could have a substantial negative effect on the Company’s liquidity. If DuPont is unable to generate sufficient cash flow or maintain access to adequate external financing, including from significant disruptions in the global credit markets, it could restrict the Company’s current operations, activities under its current and future stock buyback programs, and the Company’s growth opportunities, which could adversely affect the Company’s operating results.
A significant percentage of the Company’s net sales are generated from the Company’s international operations and are subject to economic, political, regulatory, foreign exchange and other risks.
The percentage of net sales generated by the international operations of DuPont, including U.S. exports, was approximately 65 percent of net sales on a continuing operations basis for the three months ended June 30, 2019. With Asia Pacific as the Company’s largest and currently highest growth region, DuPont expects the percentage of the Company’s net sales derived from international operations to continue to be significant. Risks related to international operations include:
- difficulties and costs associated with complying with a wide variety of complex, and often conflicting, laws, treaties and regulations, including antitrust regulations;
- restrictions on, as well as difficulties and costs associated with, the repatriation of cash from foreign countries to the United States and the allocation of revenues or distributions of cash between the Company’s foreign subsidiaries;
- exchange control regulations;
- fluctuations in foreign exchange rates;
- labor compliance costs, including wage, salary and benefit controls and other costs associated with a global workforce, as will as difficulties in hiring and maintaining a qualified staff outside of the United States, especially in the Asia Pacific region;
- government mandated price controls;
- foreign investment laws;
- potential for changes in global trade policies, including import, export and other trade restrictions (such as sanctions and embargoes) and tariffs;
- trends such as populism, economic nationalism and negative sentiment toward multinational companies, as well as government takeover or nationalization of businesses; and
- instability and uncertainty arising from the global geopolitical environment and the evolving international and domestic political, regulatory and economic landscape.
These and other factors can impair the Company’s flexibility in modifying product, marketing, pricing or other strategies for growing the Company’s businesses, as well as the Company’s ability to improve productivity and maintain acceptable operating margins.
The Company’s international operations expose it to fluctuations in foreign currencies relative to the U.S. dollar, which could adversely affect the Company’s results of operations. For its continuing operations as of the six months ended June 30, 2019, the Company’s largest currency exposures are the European euro and Chinese renminbi. U.S. dollar fluctuations against foreign currency have an impact to commercial prices and raw material costs in some cases and could result in local price increases if the price or raw material costs is denominated in U.S. dollar.
Sales and expenses of the Company’s non-U.S. businesses are also translated into U.S. dollars for reporting purposes and fluctuations of foreign currency against the U.S. dollar could impact U.S. dollar-denominated earnings. In addition, the Company’s assets and liabilities denominated in foreign currencies can also be impacted by foreign currency exchange rates against the U.S. dollar, which could result in exchange gain or loss from revaluation.
DuPont also faces exchange rate risk from the Company’s investments in subsidiaries owned and operated in foreign countries.
DuPont has a balance sheet hedging program and actively looks for opportunities in managing currency exposures related to earnings. However, foreign exchange hedging activities bear a financial cost and may not always be available to it or be successful in completely mitigating such exposures.
DuPont generates significant amounts of cash outside of the United States that is invested with financial and non-financial counterparties. While DuPont employs comprehensive controls regarding global cash management to guard against cash or investment loss and to ensure the Company’s ability to fund the Company’s operations and commitments, a material disruption to the counterparties with whom DuPont transacts business could expose it to financial loss.
Any one or more of the above factors could adversely affect the Company’s international operations and could significantly affect the Company’s business, results of operations, financial condition and cash flows.
Volatility in energy and raw material costs could have a significant impact on the Company’s sales and earnings.
The Company’s manufacturing processes consume significant amounts of energy and raw materials, the costs of which are subject to worldwide supply and demand as well as other factors beyond the Company’s control. Significant variations in the cost of energy, which primarily reflect market prices for oil, natural gas and raw materials, affect the Company’s operating results from period to period. Legislation to address climate change by reducing greenhouse gas emissions, creating a carbon tax or implementing a cap and trade program could create increases in energy costs and price volatility.
When possible, DuPont purchases raw materials through negotiated long-term contracts to minimize the impact of price fluctuations. Additionally, DuPont uses over-the-counter and exchange traded derivative commodity instruments to hedge the Company’s exposure to price fluctuations on certain raw material purchases, including food ingredients. DuPont also takes actions to offset the effects of higher energy and raw material costs through selling price increases, productivity improvements and cost reduction programs. Success in offsetting higher raw material costs with price increases is largely influenced by competitive and economic conditions and could vary significantly depending on the market served. As a result, volatility in these costs may negatively impact the Company’s business, results of operations, financial condition and cash flows.
The Company’s results will be affected by competitive conditions and customer preferences.
Demand for the Company’s products, which impacts revenue and profit margins, will be affected by (i) the development and timing of the introduction of competitive products; (ii) the Company’s response to downward pricing trends to stay competitive; (iii) changes in customer order patterns, such as changes in the levels of inventory maintained by customers and the timing of customer purchases which may be affected by announced price changes, changes in the Company’s incentive programs, or the customer’s ability to achieve incentive goals; (iv) the impact of tariffs or trade disputes on availability of raw materials; and (v) changes in customers’ preferences for the Company’s products, including the success of products offered by the Company’s competitors, and changes in customer’s designs for their products that can affect the demand for some of the Company’s products.
Additionally, success in achieving the Company’s growth objectives is significantly dependent on the timing and market acceptance of the Company’s new product offerings, including the Company’s ability to renew the Company’s pipeline of new product offerings and to bring those offerings to market. This ability may be adversely affected by difficulties or delays in product development, such as the inability to identify viable new products, obtain adequate intellectual property protection, or gain market acceptance of new products. There are no guarantees that new products will prove to be commercially successful. The Company’s success will depend on several factors, including the Company’s ability to:
- correctly identify customer needs and preferences and predict future needs and preferences;
- allocate the Company’s research & development funding to products and services with higher growth prospects;
- anticipate and respond to the Company’s competitors’ development of new products and services and technological innovations;
- differentiate the Company’s offerings from the Company’s competitors’ offerings and avoid commoditization;
- innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that may have valuable applications in the Company’s served markets;
- obtain adequate intellectual property rights with respect to key technologies before the Company’s competitors do;
- successfully commercialize new technologies in a timely manner, price them competitively and cost-effectively manufacture and deliver sufficient volumes of new products of appropriate quality on time;
- obtain necessary regulatory approvals of appropriate scope; and
- stimulate customer demand for, and convince customers, to adopt new technologies.
There are no guarantees that new product offerings will prove to be commercially successful. Additionally, the Company’s expansion into new markets may result in greater-than-expected risks, liabilities and expenses.
The costs of complying with evolving regulatory requirements could negatively impact the Company’s business, results of operations, financial condition and cash flows. Actual or alleged violations of environmental laws or permit requirements could result in restrictions or prohibitions on plant operations and substantial civil or criminal sanctions, as well as the assessment of strict liability and/or joint and several liability.
DuPont continues to be subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances relating to pollution, protection of the environment, greenhouse gas emissions, and the generation, storage, handling, transportation, treatment, disposal and remediation of hazardous substances and waste materials. Costs and capital expenditures relating to environmental, health or safety matters are subject to evolving regulatory requirements and depend on the timing of the promulgation and enforcement of specific standards which impose the requirements. Moreover, changes in environmental regulations could inhibit or interrupt the Company’s operations, or require modifications to the Company’s facilities. Changes to regulations or the implementation of additional regulations, especially in certain highly regulated markets served by the Company’s Nutrition & Biosciences businesses, such as regulatory modernization of food safety laws and evolving standards and regulations affecting pharmaceutical excipients, or in reaction to new or next-generation technologies, including advances in protein engineering, gene editing and gene mapping, or novel uses of existing technologies may result in significant costs or capital expenditures or require changes in business practice that could result in reduced margins or profitability.
Accordingly, environmental, health or safety regulatory matters could result in significant unanticipated costs or liabilities causing a negative impact on the Company’s business, cash flows and results of operations.
The Company’s business, results of operations and reputation could be adversely affected by industry-specific risks including process safety and product stewardship/regulatory compliance issues.
DuPont is subject to risks which include, but are not limited to, product safety or quality; shifting consumer preferences; federal, state, and local regulations on manufacturing or labeling; environmental, health and safety regulations; and customer product liability claims. While DuPont maintains general liability insurance, the amount of liability that may result from certain of these risks may not always be covered by, or could exceed, the applicable insurance coverage. In addition, negative publicity related to product liability, food safety, safety, health and environmental matters may damage the Company’s reputation. The occurrence of any of the matters described above could adversely affect the Company’s business, results of operations, financial condition and cash flows.
In most jurisdictions, DuPont must test the safety, efficacy and environmental impact of the Company’s products to satisfy regulatory requirements and obtain the needed approvals. In certain jurisdictions, DuPont must periodically renew the Company’s approvals, which may require it to demonstrate compliance with then-current standards. The regulatory approvals process is lengthy, complex and in some markets unpredictable, with requirements that can vary by product, technology, industry and country. Additionally, the regulatory environment may be impacted by the activities of non-governmental organizations and special interest groups and stakeholder reactions to the actual or perceived impacts of new technology, products or processes on safety, health and the environment. Obtaining and maintaining regulatory approvals will require submitting a significant amount of information and data, which may require participation from technology providers. Regulatory standards and trial procedures are continuously changing. The pace of change together with the lack of regulatory harmony could result in unintended noncompliance. To maintain the Company’s right to produce or sell existing products or to commercialize new products, DuPont must be able to demonstrate the Company’s ability to satisfy the requirements of regulatory agencies.
The failure to meet existing and new requirements or receive necessary permits or approvals could have near- and long-term effects on the Company’s ability to produce and sell certain current and future products, which could significantly increase operating costs and adversely affect the Company’s business, results of operations, financial condition and cash flows.
The Company’s business, results of operations, financial condition and cash flows could be adversely affected by interruption of the Company’s supply chain, information technology or network systems and other business disruptions.
Supply chain disruptions, plant and/or power outages, labor disputes and/or strikes, information technology system and/or network disruptions, whether caused by acts of sabotage, employee error, malfeasance or other actions, geo-political activity, weather events and natural disasters, including hurricanes or flooding that impact coastal regions, could seriously harm the Company’s operations as well as the operations of the Company’s customers and suppliers. In addition, terrorist attacks and natural disasters have increased stakeholder concerns about the security and safety of chemical production and distribution.
Supply chain and other business disruptions may also be caused by security breaches, which could include, for example, attacks on information technology and infrastructure by hackers, viruses, breaches due to employee error, malfeasance or other actions or other disruptions. DuPont and/or the Company’s suppliers may fail to effectively prevent, detect and recover from these or other security breaches and, therefore, such breaches could result in misuse of the Company’s assets, loss of property including trade secrets and confidential or personal information, some of which is subject to privacy and security laws, and other business disruptions. As a result, DuPont may be subject to legal claims or proceedings, reporting errors, processing inefficiencies, negative media attention, loss of sales, interference with regulatory compliance which could result in sanctions or penalties, liability or penalties under privacy laws, disruption in the Company’s operations, and damage to the Company’s reputation, which could adversely affect the Company’s business, results of operations, financial condition and cash flows.
Like most major corporations, DuPont is the target of industrial espionage, including cyber-attacks, from time to time. DuPont has determined that these attacks have resulted, and could result in the future, in unauthorized parties gaining access to certain confidential business information. Although management does not believe that DuPont has experienced any material losses to date related to these security breaches, including cybersecurity incidents, there can be no assurance that DuPont will not suffer such losses in the future.
DuPont seeks to actively manage the risks within the Company’s control that could lead to business disruptions and security breaches. As these threats continue to evolve, particularly around cybersecurity, DuPont may be required to expend significant resources to enhance the Company’s control environment, processes, practices and other protective measures. Despite these efforts, such events could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.
Enforcing the Company’s intellectual property rights, or defending against intellectual property claims asserted by others, could adversely affect the Company’s business, results of operations, financial condition and cash flows.
Intellectual property rights, including patents, trade secrets, know-how and other confidential information, trademarks, tradenames and other forms of trade dress, are important to the Company’s business. DuPont endeavors to protect the Company’s intellectual property rights in jurisdictions in which the Company’s products are produced or used and in jurisdictions into which the Company’s products are imported. However, DuPont may be unable to obtain protection for the Company’s intellectual property in key jurisdictions. Further, changes in government policies and regulations, including changes made in reaction to pressure from non-governmental organizations, or the public generally, could impact the extent of intellectual property protection afforded by such jurisdictions.
DuPont has designed and implemented internal controls intended to restrict access to and distribution of the Company’s intellectual property. Despite these precautions, the Company’s intellectual property is vulnerable to unauthorized access through employee error or actions, theft and cybersecurity incidents, and other security breaches. When unauthorized access and use or counterfeit products are discovered, DuPont considers the matter for report to governmental authorities for investigation, as appropriate, and take measures to mitigate any potential impact. Protecting intellectual property related to biotechnology is particularly challenging because theft is difficult to detect and biotechnology can be self-replicating. Accordingly, the impact of such theft can be significant.
Competitors are increasingly challenging the Company’s intellectual property positions, and the potential outcomes can be highly uncertain. Third parties may also claim the Company’s products violate their intellectual property rights. Defending such claims, even those without merit, is time-consuming and expensive. In addition, as a result of such claims, DuPont has and could be required in the future to enter into license agreements, develop non-infringing products or engage in litigation that could be costly. If challenges are resolved adversely, it could negatively impact the Company’s ability to obtain licenses on competitive terms, commercialize new products and generate sales from existing products.
In addition, because of the rapid pace of technological change, the confidentiality of patent applications in some jurisdictions and/or the uncertainty in predicting the outcome of complex proceedings relating to ownership or the scope of protection of patents relating to certain emerging technologies, competitors may be unexpectedly issued patents that DuPont does not anticipate. These patents could reduce the value of the Company’s commercial or pipeline products or, to the extent they cover key technologies on which DuPont has unknowingly relied, require it to seek to obtain licenses or cease using the technology, no matter how valuable to the Company’s business. If DuPont decided to obtain licenses to continue using the technology, it cannot ensure DuPont would be able to obtain such a license on acceptable terms.
Legislation and jurisprudence on patent protection is evolving, and changes in laws could affect the Company’s ability to obtain or maintain patent protection for the Company’s products.
Any one or more of the above factors could significantly affect the Company’s business, results of operations, financial condition and cash flows.
Increased concerns regarding chemicals in commerce and their potential impact on the environment have resulted in more restrictive regulations, may lead to new regulations and compliance may be costly.
Concerns about chemicals and biotechnology, as well as their potential impact on health and the environment, reflect a growing trend in societal demands for increasing levels of product safety and environmental protection. These concerns could manifest themselves in stockholder proposals, preferred purchasing, delays or failures in obtaining or retaining regulatory approvals, delayed product launches, lack of market acceptance, product discontinuation, continued pressure for and adoption of more stringent regulatory intervention and litigation. These concerns could also influence public perceptions, the viability or continued sales of certain of the Company’s products, the Company’s reputation and the cost to comply with regulations and, as a result, could have a negative impact on the Company’s business, results of operations and financial condition.
An impairment of goodwill or intangible assets could negatively impact the Company’s financial results.
At least annually, DuPont must assess both goodwill and indefinite-lived intangible assets for impairment. Intangible assets with finite lives are tested for impairment when events or changes in circumstances indicate their carrying value may not be recoverable. If testing indicates that goodwill or intangible assets are impaired, their carrying values will be written down based on fair values with a charge against earnings. Where DuPont utilizes discounted cash flow methodologies in determining fair values, continued weak demand for a specific product line or business could result in an impairment. Accordingly, any determination requiring the write-off of a significant portion of goodwill or intangible assets could negatively impact the Company’s results of operations.
As a result of the Merger and related acquisition method of accounting, Historical EID’s assets and liabilities were measured at fair value, and any declines in projected cash flows could have a material, negative impact on the fair value of the Company’s reporting units and assets. Future impairments of the Company’s goodwill or intangible assets also could be recorded due to changes in assumptions, estimates or circumstances and the magnitude of such impairments may be material to it.
Failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions could adversely impact the Company’s business, results of operations, financial condition and cash flows.
DuPont from time to time evaluates acquisition candidates that may strategically fit the Company’s business and/or growth objectives. If DuPont is unable to successfully integrate and develop acquired businesses, DuPont could fail to achieve anticipated synergies and cost savings, including any expected increases in revenues and operating results, which could have a material adverse effect on the Company’s financial results. DuPont expects to continually review the Company’s portfolio of assets for contributions to the Company’s objectives and alignment with the Company’s growth strategy. The Letter Agreement between the Company and Corteva limits DuPont’s ability to separate certain businesses and assets to third parties without assigning certain of its indemnification obligations under the Separation and Distribution Agreement to the transferee of such businesses and assets or meeting certain other alternative conditions. DuPont may be unable to meet the conditions under the Letter Agreement, if applicable.
Even if the conditions under the Letter Agreement are met or are not applicable, DuPont may not be successful in separating underperforming or non-strategic assets, and gains or losses on the divestiture of, or lost operating income from, such assets may affect the Company’s earnings. Moreover, DuPont might incur asset impairment charges related to acquisitions or divestitures that reduce the Company’s earnings. In addition, if the execution or implementation of acquisitions, divestitures, alliances, joint ventures and other portfolio actions is not successful, it could adversely impact the Company’s business, results of operations, financial condition and cash flows.
The Company’s results of operations could be adversely affected by litigation and other commitments and contingencies.
DuPont faces risks arising from various unasserted and asserted litigation matters, including product liability, patent infringement and other intellectual property disputes, contract and commercial litigation, claims for damage or personal injury, antitrust claims, governmental regulations and other actions. An adverse outcome in any one or more of these matters could be material to the Company’s business, results of operations, financial condition and cash flows.
In the ordinary course of business, DuPont may make certain commitments, including representations, warranties and indemnities relating to current and past operations, including those related to divested businesses, and DuPont may issue guarantees of third-party obligations. If DuPont is required to make payments as a result, they could exceed the amounts accrued therefor, thereby adversely affecting the Company’s results of operations.
DuPont is subject to numerous laws, regulations and mandates globally which could adversely affect the Company’s operating results and forward strategy.
DuPont does business globally in more than 60 countries. DuPont is required to comply with the numerous and far-reaching laws and regulations administered by United States federal, state, local and foreign governmental authorities. DuPont is required to comply with other general business regulations covering areas such as income taxes, anti-corruption, anti-bribery, global trade, trade sanctions, environmental protections, product safety, and handling and production of regulated substances. DuPont expects to frequently face challenges from U.S. and foreign tax authorities regarding the amount of taxes due. These challenges may include questions regarding the timing and amount of deductions and the allocation of income among various tax jurisdictions.
In evaluating the exposure associated with various tax filing positions, DuPont expects to record reserves for estimates of potential additional tax DuPont may owe. Any failure to comply with applicable laws and regulations or appropriately resolve these challenges could subject it to administrative, civil and criminal remedies including fines, penalties, disgorgement, injunctions and recalls of the Company’s products, and damage to the Company’s reputation.
Governmental policies, including antitrust and competition law, trade restrictions, regulations related to medical applications and devices, food safety regulations, sustainability requirements, traceability and other government regulations and mandates, can impact the Company’s ability to execute this strategy successfully. See also “-A significant percentage of the Company’s net sales are generated from the Company’s international operations and are subject to the economic, political, regulatory, foreign exchange and other risks.”
Failure to maintain a streamlined operating model and sustain operational improvements may reduce the Company’s profitability or adversely impact the Company’s business, results of operations, financial condition and cash flows.
The Company’s profitability and margin growth will depend in part on the Company’s ability to maintain a streamlined operating model and drive sustainable improvements, through actions and projects, such as consolidation of manufacturing facilities, transitions to cost-competitive regions and product line rationalizations. A variety of factors may adversely affect the Company’s ability to realize the targeted cost synergies, including failure to successfully optimize the Company’s facilities footprint, the failure to take advantage of the Company’s global supply chain, the failure to identify and eliminate duplicative programs, and the failure to otherwise integrate Historical EID’s or Historical Dow’s respective specialty products businesses, including their technology platforms. There can be no assurance that DuPont is be able to achieve or sustain any or all of the cost savings generated from restructuring actions.
The Company’s U.S. and non-U.S. tax liabilities will be dependent, in part, upon the distribution of income among various jurisdictions in which DuPont operate.
The Company’s future results of operations could be adversely affected by changes in the effective tax rate as a result of a change in the mix of earnings in countries with differing statutory tax rates, changes in tax laws, regulations and judicial rulings (or changes in the interpretation thereof), changes in generally accepted accounting principles, changes in the valuation of deferred tax assets and liabilities, changes in the amount of earnings permanently reinvested offshore, the results of audits and examinations of previously filed tax returns and continuing assessments of the Company’s tax exposures and various other governmental enforcement initiatives. The Company’s tax expense includes estimates of tax reserves and reflects other estimates and assumptions, including assessments of future earnings of the Company which could impact the valuation of the Company’s deferred tax assets. Changes in tax laws or regulations, including further regulatory developments arising from U.S. tax reform legislation as well as multi-jurisdictional changes enacted in response to the action items provided by the Organization for Economic Co-operation and Development (OECD), will increase tax uncertainty and impact the Company’s provision for income taxes
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $5.47bn | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $10.88bn | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $3.50bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $7.12bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $232.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $499.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $642.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $1.37bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $155.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $64.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$571.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$50.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.76 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | −$0.76 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 749,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 749,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Share repurchases | 3 months2019-04-01 to 2019-06-30 | $102.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-06-30 | $1.66bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $10.62bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $70.84bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $6.46bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $28.27bn | us-gaap:Liabilities |
| Long-term debt | At period end2019-06-30 | −$15.61bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2019-06-30 | $1.62bn | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2019-06-30 | $1.62bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2019-06-30 | $42.01bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001666700-19-000065. Last ingested by Listed: Nov 10, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.